Clinical Trial Landscape
Evolving Clinical Trial Landscape: Where are clinical sponsors focusing their efforts?
In 2021 there were a total of 413,028 registered studies globally.
Breaking this down (and according to our study) in 2022 Life Sciences organisations intend to focus (or indeed are already focusing) their clinical studies on what is outlined in the chart in this section.
The number of clinical trials focused on novel and next-generation therapeutics, such as cell and gene therapies, continues to increase – from 23% in 2021 to 36% in 2022. Many of these trials focus on rare diseases where no effective treatments exist. They potentially offer patients the prospect of meaningful clinical improvements, even cures, after a single dose.
In which of the following areas are your clinical studies focused this year?
Optimising the conduct of clinical trials
Following on from the previous section, 85% of Life Sciences organisations say they plan to optimise the conduct of clinical trials over the next 12 months.
This ties in closely with their efforts to streamline processes, reduce cost and increase efficiency within trials.
When asked specifically about where they plan to prioritise their efforts, our respondents highlighted a broad spread. There was little to separate the top five priorities as shown in the chart, which perhaps highlights uncertainty about where best to start or focus efforts.
Over the course of 2020, the industry pivoted towards digital technology in a bid to overcome disruption to clinical trials and maintain patients on treatment.
The data in this 2022 Arkivum survey suggests that many have now adopted remote monitoring strategies, so disruption is no longer such a threat.
In 2021, 47% of respondents said they would prioritise increasing remote treatment; this compares to 33% in 2022; in 2021, 38% said it was a challenge to run a study remotely, while the figure for 2022 is 30%.
You can access the full chart here.
As organisations look to optimise conduct of clinical trials, which of the following will be a priority for your organisation over the next 12 months?
"85% of Life Sciences organisations say they plan to optimise the conduct of clinical trials over the next 12 months."
Challenges running clinical trials - 2021 vs. 2022
Managing data from multiple CROs
Running a study remotely
Keeping up with quality regulations
